Important Update: Class Action Lawsuit Against Semler Scientific, Inc. Highlights Investor Risks
On October 8, 2025, Pomerantz LLP announced a class action lawsuit against Semler Scientific, Inc. (SMLR), raising significant concerns for affected investors. The lawsuit claims that Semler, along with particular officers or directors, may have engaged in fraudulent activities or unlawful business practices, compromising the integrity of their financial reporting and ultimately impacting shareholders.
Investors who have suffered losses from their investments in Semler are urged to act swiftly and connect with the law firm for essential guidance. Pomerantz encourages individuals to contact Danielle Peyton at 646-581-9980 or via email at [email protected] when reaching out. It’s vital for affected investors to share their contact details, including their mailing address, phone number, and the number of shares they have acquired in the company.
The concern escalated when, on February 28, 2025, Semler disclosed in their annual report that they were under investigation by the U.S. Department of Justice (DOJ) regarding allegations tied to False Claims Act violations tied to their QuantaFlo device. This announcement triggered a significant fall in Semler's stock price, which plunged by $4.03 or approximately 9.4% to close at $38.89 per share by March 3, 2025.
In light of an ongoing DOJ investigation, Semler faced scrutiny as they admitted to participating in unsuccessful negotiations aimed at resolving the issues highlighted by the investigation. This chapter unfurled further on April 15, 2025, when Semler announced they had reached a preliminary agreement with the DOJ for a settlement amount of $29.75 million regarding all claims. Nevertheless, this outcome continued to negatively affect the stock, with shares dropping by $3.40 or 9.88% to $31.00 the following day.
Investors still have time to ensure their voices are heard in this legal battle, with the deadline to appoint a Lead Plaintiff set for October 28, 2025. Prospective class members are encouraged to acquire and review the formal complaint filed with Pomerantz Law, which is easily accessible via www.pomerantzlaw.com.
Pomerantz LLP is a well-known law firm based in New York, with a longstanding reputation for excellence in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, recognized as a pioneer in the domain of securities class actions, the firm has dedicated over 85 years to standing up for investors against corporate misbehavior. Throughout its history, Pomerantz has successfully recovered significant damages for numerous class members affected by securities fraud and breaches of fiduciary duty.
This class action signals a crucial development for investors in Semler Scientific, representing a chance to recover their losses and hold accountable those responsible for the alleged misconduct. As the situation unfolds, stakeholders should remain vigilant and informed to safeguard their interests in the volatile landscape of corporate governance and investor rights.
For immediate assistance concerning the class action against Semler and details on joining, please reach out to Pomerantz LLP directly, ensuring you have a place in this significant legal movement.
Investors who have suffered losses from their investments in Semler are urged to act swiftly and connect with the law firm for essential guidance. Pomerantz encourages individuals to contact Danielle Peyton at 646-581-9980 or via email at [email protected] when reaching out. It’s vital for affected investors to share their contact details, including their mailing address, phone number, and the number of shares they have acquired in the company.
The concern escalated when, on February 28, 2025, Semler disclosed in their annual report that they were under investigation by the U.S. Department of Justice (DOJ) regarding allegations tied to False Claims Act violations tied to their QuantaFlo device. This announcement triggered a significant fall in Semler's stock price, which plunged by $4.03 or approximately 9.4% to close at $38.89 per share by March 3, 2025.
In light of an ongoing DOJ investigation, Semler faced scrutiny as they admitted to participating in unsuccessful negotiations aimed at resolving the issues highlighted by the investigation. This chapter unfurled further on April 15, 2025, when Semler announced they had reached a preliminary agreement with the DOJ for a settlement amount of $29.75 million regarding all claims. Nevertheless, this outcome continued to negatively affect the stock, with shares dropping by $3.40 or 9.88% to $31.00 the following day.
Investors still have time to ensure their voices are heard in this legal battle, with the deadline to appoint a Lead Plaintiff set for October 28, 2025. Prospective class members are encouraged to acquire and review the formal complaint filed with Pomerantz Law, which is easily accessible via www.pomerantzlaw.com.
Pomerantz LLP is a well-known law firm based in New York, with a longstanding reputation for excellence in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, recognized as a pioneer in the domain of securities class actions, the firm has dedicated over 85 years to standing up for investors against corporate misbehavior. Throughout its history, Pomerantz has successfully recovered significant damages for numerous class members affected by securities fraud and breaches of fiduciary duty.
This class action signals a crucial development for investors in Semler Scientific, representing a chance to recover their losses and hold accountable those responsible for the alleged misconduct. As the situation unfolds, stakeholders should remain vigilant and informed to safeguard their interests in the volatile landscape of corporate governance and investor rights.
For immediate assistance concerning the class action against Semler and details on joining, please reach out to Pomerantz LLP directly, ensuring you have a place in this significant legal movement.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.